Search
The discovery suggests a potential new treatment approach for certain cancers.
Every year, the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) awards fellowships to students who show promise in their scientific endeavors at GSK.
New research from scientists at the Sloan Kettering Institute helps explain how growing tumors escape our immune defenses.
Gerstner Sloan Kettering sponsored a daylong symposium for undergraduates and their faculty advisors to meet Gerstner Sloan Kettering leaders and graduate students while enjoying faculty talks, student posters, and a visit to Memorial Sloan Kettering research facilities.
Memorial Sloan Kettering Cancer Center researchers have identified a feature in the DNA of breast cancer cells that might indicate the likelihood a woman's disease will become life threatening.
Methods to generate stem cells have given scientists new ways to study some diseases and identify potential drugs, and could one day be used to rebuild diseased or damaged tissues in patients.
Understanding tumor heterogeneity may be the next big quest in cancer science, as differences between cells within a tumor can have important consequences for how cancers are diagnosed and treated.
Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after the disease becomes resistant to standard treatments.
In an interview in September 2020, Dr. Studer spoke about what he hopes he and his fellow investigators can accomplish with this generous support.
Memorial Sloan Kettering Cancer Center chemist Samuel J. Danishefsky will be honored with three major awards this spring. Dr. Danishefsky is the incumbent of a Eugene W. Kettering Chair and a member of the Molecular Pharmacology and Chemistry Program in the Sloan Kettering Institute.